Pfizer Hones Biosimilars Approach For Individual Countries
Executive Summary
The company has biosimilars of Rituxan, Herceptin and Remicade in clinical trials and a biosimilar to Humira is about to enter Phase I; Pfizer is pursuing the biosimilar pathway for all of its candidates.
You may also be interested in...
Celltrion Gears Up For Phase III Trial For Biosimilar Of Roche’s Rituxan
Korea’s Celltrion said it is on path to a new Phase III trial design of a biosimilar of Roche’s Rituxan after presenting positive Phase I trial data in San Diego in late October.
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.
Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.